BR0116552A - Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão - Google Patents

Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão

Info

Publication number
BR0116552A
BR0116552A BR0116552-6A BR0116552A BR0116552A BR 0116552 A BR0116552 A BR 0116552A BR 0116552 A BR0116552 A BR 0116552A BR 0116552 A BR0116552 A BR 0116552A
Authority
BR
Brazil
Prior art keywords
angina
hypertension
treatment
prevention
pharmaceutical composition
Prior art date
Application number
BR0116552-6A
Other languages
English (en)
Inventor
Gerrit Jan Bouke Ettema
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BR0116552A publication Critical patent/BR0116552A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"HEMI-MALEATO DE AMLODIPINA, PROCESSO, MéTODO PARA O TRATAMENTO OU PREVENçãO DE ANGINA OU HIPERTENSãO, COMPOSIçãO FARMACêUTICA PARA USO NO TRATAMENTO E/OU DE ANGINA OU DA HIPERTENSãO". O hemi-maleato de amlodipina é útil como um bloqueador do canal cálcio e pode ser usada para tratar ou prevenir a angina ou a hipertensão.
BR0116552-6A 2000-12-29 2001-08-15 Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão BR0116552A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25860300P 2000-12-29 2000-12-29
US80935601A 2001-03-16 2001-03-16
PCT/NL2001/000602 WO2002053539A1 (en) 2000-12-29 2001-08-15 Amlodipine hemimaleate
BE2001/0711A BE1014454A6 (nl) 2000-12-29 2001-11-05 Amlodipinehemimaleaat.

Publications (1)

Publication Number Publication Date
BR0116552A true BR0116552A (pt) 2004-02-03

Family

ID=29740327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116552-6A BR0116552A (pt) 2000-12-29 2001-08-15 Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão

Country Status (10)

Country Link
US (1) US6538012B2 (pt)
EP (1) EP1309557B9 (pt)
AT (1) ATE315026T1 (pt)
BE (1) BE1014454A6 (pt)
BR (1) BR0116552A (pt)
CA (1) CA2433190C (pt)
DE (1) DE60116514T2 (pt)
ES (1) ES2254495T4 (pt)
MX (1) MXPA03005884A (pt)
WO (1) WO2002053539A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053541A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
WO2002053542A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Process for making amlodipine maleate
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
MXPA03005882A (es) * 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
WO2004067512A1 (en) * 2003-01-27 2004-08-12 Hanmi Pharm. Co., Ltd. Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
ES2886067T3 (es) 2016-10-07 2021-12-16 Silvergate Pharmaceuticals Inc Formulaciones de amlodipina
CA3096101A1 (en) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN116332832A (zh) * 2023-03-29 2023-06-27 安徽美致诚药业有限公司 一种马来酸左旋氨氯地平无定型晶型及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4983740A (en) 1986-08-04 1991-01-08 Adir Et Compagnie Process for 1,4-dihydropyridine compounds
FR2602231B1 (fr) * 1986-08-04 1988-10-28 Adir Nouveaux derives de la dihydro-1,4 pyridine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
WO1993006082A1 (en) 1991-09-13 1993-04-01 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropyridines
US5389654A (en) 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
HU221810B1 (hu) 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
ZA9810320B (en) 1997-11-14 2000-05-11 Gea Farmaceutisk Fabrik As Process for the preparation of 1,4-dihydropyridines and novel compounds of use for such purpose.
PL189666B1 (pl) 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
ES2151850B1 (es) 1998-10-26 2001-08-16 Esteve Quimica Sa Intermedio para la sintesis de amlodipino para su obtencion y utilizacion correspondiente.
GB9827431D0 (en) 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9827387D0 (en) 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process

Also Published As

Publication number Publication date
DE60116514D1 (de) 2006-03-30
EP1309557A1 (en) 2003-05-14
EP1309557B9 (en) 2006-11-15
US6538012B2 (en) 2003-03-25
ES2254495T4 (es) 2007-06-16
DE60116514T2 (de) 2006-08-17
EP1309557B1 (en) 2006-01-04
CA2433190A1 (en) 2002-07-11
CA2433190C (en) 2005-11-15
MXPA03005884A (es) 2005-04-08
BE1014454A6 (nl) 2003-10-07
ES2254495T3 (es) 2006-06-16
ATE315026T1 (de) 2006-02-15
US20020128297A1 (en) 2002-09-12
WO2002053539A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
WO2001066564A3 (en) Gamma-secretase inhibitors
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
BR0108657A (pt) Composto, processo para a preparação e uso do mesmo, e, processo para a preparação da (s)-alfa-etil-2-oxo-1-pirrolidina acetamida ou (r)-alfa-etil-2-oxo-1-pirrolidina acetamida
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
NO20020384D0 (no) Amin og aminderivater som ligander for neuropeptid Y Y5 reseptor anvendelig ved behandling av fedme og andre forstyrrelser
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
WO2003006670A3 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
BR0116552A (pt) Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
BR0101230A (pt) Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina
WO2002098850A3 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
NO995431L (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
BR0116553A (pt) Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
EP1183011A4 (en) METHOD FOR THE TREATMENT OF ANGINA AND / OR SIMILAR ILLNESSES AND THE MEDICINAL PRODUCTS AND KITS THEREOF
BR9909260A (pt) Processo para o preparo de (r)-alfa-(2,3-dimetóxifenil)-1-[2-(4-fluoro-fenil)etil]-4-pi peridinametanol
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
DK1265856T3 (da) Hidtil ukendt fremgangsmåde til fremstillingen af alpha-(2,4-disulfophenyl)-N-tert-butylnitron og farmaceutisk acceptable salte deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.